MRKR VS PPBT Stock Comparison

PerformanceTechnicalsEarningsProfitVolatility
PerformanceTechnicalsEarningsProfitVolatility

Performance

MRKR
10/100

MRKR returned -20.79% in the last 12 months. Based on SPY's performance of -13.80%, its performance is below average giving it a score of 10 of 100.

PPBT
10/100

PPBT returned -52.51% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Technicals

MRKR
21/100

MRKR receives a 21 of 100 based on 14 indicators. 2 are bullish, 10 are bearish.

PPBT
11/100

PPBT receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

MRKR
10/100

MRKR has missed earnings 6 times in the last 20 quarters.

PPBT
10/100

PPBT has missed earnings 7 times in the last 20 quarters.

Profit

MRKR
10/100

Out of the last 20 quarters, MRKR has had 0 profitable quarters and has increased their profits year over year on 0 of them.

PPBT
11/100

Out of the last 20 quarters, PPBT has had 1 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

MRKR
58/100

MRKR has had a higher than average amount of volatility over the last 12 months giving it a score of 57 of 100.

PPBT
48/100

PPBT has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Marker Therapeutics, Inc. Common Stock Summary

Nasdaq / MRKR
Healthcare
Biotechnology
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.

Purple Biotech Ltd. American Depositary Shares Summary

Nasdaq / PPBT
Healthcare
Biotechnology
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.